Nasus Pharma: Clinical Trials

3 trials sponsored by Nasus Pharma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 enrolling by invitation, 1 completed. 3 Phase 2, 2 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 23Enrolling by invitation 2, Completed 1
Phase 12Completed 1, Enrolling by invitation 1
Phase 31Enrolling by invitation 1

Follow Nasus Pharma: new trials by email

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic Rhinitis
FMXIN002 single dose, Epinephrine autoinjector single dose, FMXIN002 single dose + NAC - Anaphylaxis, Allergy
Phase 1 / Phase 2Enrolling by invitationNasus Pharma502025-11-032025-11-14
FMXIN002 in Patients at Risk of Anaphylaxis
Epinephrine 4mg nasal powder spray, Adrenalin 0.5mg Injectable Product - Anaphylaxis Food
Phase 2 / Phase 3Enrolling by invitationNasus Pharma302025-06-122025-07-01
Comparative Bioavailability of Intranasal Epinephrine
A: Epinephrine injection, B: FMXIN002 3.6mg, C: FMXIN002 4.0mg - Anaphylaxis, Anaphylactic Reaction
Phase 1 / Phase 2CompletedNasus Pharma122023-08-222025-06-18

Conditions studied

Anaphylaxis (2)  ·  Hypersensitivity (1)

Interventions

Epinephrine (3)  ·  Injections (1)

Countries

Israel (2)  ·  Canada (1)

Top investigators

Arnon Elizur, Prof. (1)  ·  Mark L Freedman, MD, FRCPC (1)  ·  Yoseph Caraco, Professor (1)